Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Operating Expenses for 6 consecutive years, with $69.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 18.17% year-over-year to $69.0 million, compared with a TTM value of $266.9 million through Dec 2025, up 12.77%, and an annual FY2025 reading of $266.9 million, up 12.77% over the prior year.
  • Operating Expenses was $69.0 million for Q4 2025 at Xeris Biopharma Holdings, up from $67.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $69.7 million in Q4 2021 and bottomed at $24.9 million in Q1 2021.
  • Average Operating Expenses over 5 years is $53.4 million, with a median of $54.1 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 287.27% in 2021, then tumbled 30.68% in 2022.
  • Year by year, Operating Expenses stood at $69.7 million in 2021, then crashed by 30.68% to $48.3 million in 2022, then rose by 12.25% to $54.2 million in 2023, then grew by 7.72% to $58.4 million in 2024, then rose by 18.17% to $69.0 million in 2025.
  • Business Quant data shows Operating Expenses for XERS at $69.0 million in Q4 2025, $67.6 million in Q3 2025, and $67.1 million in Q2 2025.